← board
GALT
Galectin Therapeutics Inc.distress 5/10 · elevated risk$3.52+0%today-46% from 52w high
Metabolic / Obesity 1
Lead: MASH cirrhosis and portal hypertension · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$14M
Runway
0.7 yrs
Shares 1y
+3%
Price & events
-0.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-16.9%
1W
+12.7%
1M
+48.3%
3M
+6.2%
6M
+24.6%
1Y
+35.7%
2Y
+32.1%
5Y
+58.3%
All
Overview
- Market Cap
- $231.49M
- Volume
- 71.14K
- 52 Week Range
- $2.08 – $6.51
- Total Shares
- 65.86M
- Float Shares
- 47.19M
- Short %
- 21.38%
- % Held by Insiders
- 29.09%
- % Held by Institutions
- 21.17%
- RVOL
- 0.07x
- Beta
- 0.35
Pipeline stages · 1 programs
belapectin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-11 | Phase 2/3 | belapectinfast track | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 357 | terminated |
Catalyst news & presentations · 5
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)belapectin · Planned submission of Phase 3 protocol to FDASEC 8-K
- 2026-06-23fda agreementbelapectin · FDA agreed on composite liver outcome as primary endpoint for Phase 3 trialSEC 8-K
- June 16, 2025 at 12:00 p.m. ETconferencedata presentationsecondarybelapectin · Webcast discussing corporate presentation on belapectin clinical data and pipeline.SEC 8-K
- early 2025conferencedata presentationsecondaryPhase 3belapectin · Additional clinical updates and biomarker data from NAVIGATE trial including 36-month treatment completers.SEC 8-K
- December 2024readoutPhase 3Belapectin · Topline results from NAVIGATE trial expected.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+213% upside) · 1 analysts
- 2026-06-23HC Wainwright & Co.Buy
- 2025-12-17HC Wainwright & Co.Buy
- 2025-08-14HC Wainwright & Co.Buy
- 2025-04-02HC Wainwright & Co.Neutral
- 2024-12-27HC Wainwright & Co.Buy → Neutral
- 2024-11-15HC Wainwright & Co.Buy
Competitors — MASH cirrhosis and portal hypertension
- none identified
Recent news
- 2026-07-23Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving Average - Here's Why - MarketBeat
- 2026-07-19GALT stock gains support as Galectin Therapeutics keeps cash focus - Ad-hoc-news.de
- 2026-07-17Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
- 2026-07-16Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
- 2026-07-16Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock By Investing.com - Investing.com South Africa
- 2026-07-15Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
- 2026-07-14Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.